A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors.

Trial Profile

A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Tozasertib (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Jan 2010 Planned end date (Apr 2007) added as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Official Title amended as reported by ClinicalTrials.gov.
    • 19 Nov 2007 Status change from in progress to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top